Why Iovance Biotherapeutics Stock Was on Fire Today
An influential investment bank resumed its coverage of the company.
Overview
A new, bullish analyst take on Iovance Biotherapeutics (NASDAQ: IOVA) put the company's shares in the win column on Thursday. That analysis was published by an always-influential investment bank, and it improved sentiment on Iovance sufficiently to send the shares to an almost 6% gain.
That morning Goldman Sachs, in the person of pundit Andrea Newkirk, resumed coverage of Iovance, a biotech that concentrates on developing cancer therapies. She rated Iovance's equity a buy at a price target of $15 per share.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.